Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 968 12.24 (1.28%) Market Cap: 106.66 Bil Enterprise Value: 97.49 Bil PE Ratio: 28.60 PB Ratio: 3.95 GF Score: 94/100

Regeneron Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual) Transcript

Dec 02, 2020 / 01:00PM GMT
Release Date Price: $505.13 (-1.74%)
Christopher Joseph Raymond
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Okay. Let's go ahead and get started. Thanks, everybody, for joining us. My name is Chris Raymond. I'm one of Piper Sandler's biotech analysts. Pleased to have with us our next presenter, which is Regeneron Pharmaceuticals. We have joining us today, Regeneron's CFO, Bob Landry; and also Justin Holko, who is the VP of Investor Relations. So we've got a lot to talk about in this fireside chat format. We have about 25 minutes. So I think what we're going to have Bob do is to provide just some introductory comments, and then we'll dive into questions.

So Bob, please take it away.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Great, Chris. Good morning. Nice to see you. And good morning, good afternoon to everyone, who's joined us today. Thank you for inviting us to your conference.

So before I begin, let me start with some introductory comments. Let me remind you that today there will be remarks on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot